[(7S,9E,12R,13S,16R,17S)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(Z)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
- rifampin
- Rifampicin
- 13292-46-1
- BCP28502
- Create:2019-01-26
- Modify:2025-01-18
- Benemycin
- Rifadin
- Rifampicin
- Rifampin
- Rimactan
- Rimactane
- Tubocin
Antileprosy medicines
Antituberculosis medicines
Use (kg; approx.) in Germany (2009): >1000
Use (kg) in France (2004): 2383
Consumption (g per capita; approx.) in Germany (2009): 0.0122
Consumption (g per capita) in France (2004): 0.0394
Excretion rate: 0.18
Calculated removal (%): 42.1
H302 (98.3%): Harmful if swallowed [Warning Acute toxicity, oral]
H315 (86.7%): Causes skin irritation [Warning Skin corrosion/irritation]
H319 (86.7%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
H335 (85%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]
P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501
(The corresponding statement to each P-code can be found at the GHS Classification page.)
Aggregated GHS information provided per 60 reports by companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
Acute Tox. 4 (98.3%)
Skin Irrit. 2 (86.7%)
Eye Irrit. 2 (86.7%)
STOT SE 3 (85%)
Hazard Traits - Developmental Toxicity; Reproductive Toxicity
Authoritative List - Prop 65
Report - regardless of intended function of ingredient in the product
Volume 24: (1980) Some Pharmaceutical Drugs
Volume Sup 7: Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42, 1987; 440 pages; ISBN 92-832-1411-0 (out of print)
◉ Summary of Use during Lactation
Limited information indicates that there are low levels of rifampin in breastmilk that would not be expected to cause any adverse effects in breastfed infants. The amount of rifampin in milk is insufficient to treat tuberculosis in the breastfed infant. The Centers for Disease Control and Prevention and other professional organizations state that breastfeeding should not be discouraged in women taking rifampin. Breastmilk may be stained a yellow, orange, red or brown color.
◉ Effects in Breastfed Infants
One woman taking rifampin 450 mg, isoniazid 300 mg and ethambutol 1200 mg daily during pregnancy and rifampin 450 mg and isoniazid 300 mg for the first 7 months of lactation (extent not stated). The infant was born with mildly elevated serum liver enzymes which persisted for to 1 (alanine transferase) to 2 years (aspartate transaminase), but had no other adverse reactions.
Rifampin was used as part of multi-drug regimens to treat 2 pregnant women with multidrug-resistant tuberculosis throughout pregnancy and postpartum. Their two infants were breastfed (extent and duration not stated). At age 3.9 and 5.1 years, the children were developing normally except for hyperactivity in one.
Two mothers in Türkiye were diagnosed with tuberculosis at the 30th and 34th weeks of pregnancy. They immediately started isoniazid 300 mg, rifampin 600 mg, pyridoxine 50 mg daily for 6 months, plus pyrazinamide 25 mg/kg and ethambutol 25 mg/kg daily for 2 months. Both mothers breastfed their infants (extent not stated). Their infants were given isoniazid 5 mg/kg daily for 3 months prophylactically. Tuberculin skin tests were negative after 3 months and neither infant had tuberculosis at 1 year of age. No adverse effects of the drugs were mentioned.
A woman with leprosy took clofazimine, dapsone and rifampin during pregnancy and breastfeeding. Her infant developed skin discoloration attributed to clofazimine which reversed 3 months after cessation of breastfeeding.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
- Australian Industrial Chemicals Introduction Scheme (AICIS)Rifamycin, 3-[[(4-methyl-1-piperazinyl)imino]methyl]-https://services.industrialchemicals.gov.au/search-assessments/
- DrugBankLICENSECreative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)https://www.drugbank.ca/legal/terms_of_use
- European Chemicals Agency (ECHA)LICENSEUse of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.https://echa.europa.eu/web/guest/legal-noticeRifampicin (EC: 236-312-0)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/109156
- Hazardous Substances Data Bank (HSDB)
- New Zealand Environmental Protection Authority (EPA)LICENSEThis work is licensed under the Creative Commons Attribution-ShareAlike 4.0 International licence.https://www.epa.govt.nz/about-this-site/general-copyright-statement/
- California Office of Environmental Health Hazard Assessment (OEHHA)
- California Safe Cosmetics Program (CSCP) Product Database
- ClinicalTrials.govLICENSEThe ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
- Drugs and Lactation Database (LactMed)
- WHO Model Lists of Essential MedicinesLICENSEPermission from WHO is not required for the use of WHO materials issued under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Intergovernmental Organization (CC BY-NC-SA 3.0 IGO) license.https://www.who.int/about/policies/publishing/copyright
- EU Clinical Trials Register
- NORMAN Suspect List ExchangeLICENSEData: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0https://creativecommons.org/licenses/by/4.0/RIFAMPICIN
- International Agency for Research on Cancer (IARC)LICENSEMaterials made available by IARC/WHO enjoy copyright protection under the Berne Convention for the Protection of Literature and Artistic Works, under other international conventions, and under national laws on copyright and neighbouring rights. IARC exercises copyright over its Materials to make sure that they are used in accordance with the Agency's principles. All rights are reserved.https://publications.iarc.fr/Terms-Of-UseIARC Classificationhttps://www.iarc.fr/
- Metabolomics Workbench
- NIPH Clinical Trials Search of Japan
- PharosLICENSEData accessed from Pharos and TCRD is publicly available from the primary sources listed above. Please respect their individual licenses regarding proper use and redistribution.https://pharos.nih.gov/about
- WHO Anatomical Therapeutic Chemical (ATC) ClassificationLICENSEUse of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.https://www.whocc.no/copyright_disclaimer/
- WikipediaRifampicinhttps://en.wikipedia.org/wiki/Rifampicin
- Medical Subject Headings (MeSH)LICENSEWorks produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.https://www.nlm.nih.gov/copyright.htmlAntibiotics, Antitubercularhttps://www.ncbi.nlm.nih.gov/mesh/68000904Cytochrome P-450 CYP2B6 Inducershttps://www.ncbi.nlm.nih.gov/mesh/68065695Cytochrome P-450 CYP2C19 Inducershttps://www.ncbi.nlm.nih.gov/mesh/68065697Cytochrome P-450 CYP2C8 Inducershttps://www.ncbi.nlm.nih.gov/mesh/68065696Cytochrome P-450 CYP2C9 Inducershttps://www.ncbi.nlm.nih.gov/mesh/68065698Cytochrome P-450 CYP3A Inducershttps://www.ncbi.nlm.nih.gov/mesh/68065701Leprostatic Agentshttps://www.ncbi.nlm.nih.gov/mesh/68007917Nucleic Acid Synthesis Inhibitorshttps://www.ncbi.nlm.nih.gov/mesh/68019384
- PubChem
- GHS Classification (UNECE)GHS Classification Treehttp://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
- National Drug Code (NDC) DirectoryLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linkingFDA Drug Type and Pharmacologic Classificationhttps://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory